Sevilla

• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 … Ended recruitment
  2023-505964-13-00 5 2021-03-09 Hemophilia A
• A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended recruitment
  2022-502705-15-00 5 2021-03-08 High-risk muscle-invasive bladder cancer
• A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended recruitment
  2023-507890-17-00 5 2021-02-22 Anemia associated with myeloproliferative neoplasm (MPN)-associated my
• A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi … Ended recruitment
  2023-509516-28-00 4 2021-02-22 Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
• A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou … Ended recruitment
  2023-509405-77-00 5 2021-02-16 Colorectal cancer (BRAF V600E-mutant mCRC)
• A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in C … Ended recruitment
  2023-509604-15-00 3 2021-02-15 Advanced Renal Cell Carcinoma
• A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis. Ended recruitment
  2022-503072-84-00 5 2021-02-13 stage IIIa cardiac AL amyloidosis
• A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended recruitment
  2022-503073-11-00 5 2021-02-13 Stage IIIb cardiac AL amyloidosis
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat … Ended recruitment
  2023-507338-26-00 5 2021-02-01 Histologically documented gastric or gastroesophageal junction adenoca
• DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o … Ended recruitment
  2023-505309-18-00 9 2021-01-21 HER2-positive Metastatic Breast Cancer
• A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 … Ended recruitment
  2024-512232-30-00 10 2021-01-18 Primary Biliary Cholangitis
• "Study of chemotherapy vs immunotherapy for patients with lung cancer bounded in the thorax and completely resected" Ended recruitment
  2024-513730-38-00 5 2021-01-13 Resectable Non-small cell lung cancer
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended recruitment
  2023-504959-27-00 5 2020-12-09 Participants with Limited Stage-Small Cell Lung Cancer, who have recei
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa … Ended recruitment
  2023-506911-16-00 5 2020-12-04 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca … Ended recruitment
  2024-516653-44-00 5 2020-11-30 HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended recruitment
  2022-501645-70-00 5 2020-11-25 Crohns Disease
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc … Ended recruitment
  2022-502611-10-00 5 2020-11-24 Primary Progressive Multiple Sclerosis (PPMS)
• A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal Hyperplasia Ended recruitment
  2023-509171-16-00 5 2020-11-23 Classic Congenital Adrenal Hyperplasia (CAH)
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended recruitment
  2023-509358-72-00 5 2020-11-23 Diffuse large B-cell lymphoma
• Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk … Ended recruitment
  2023-507153-16-00 5 2020-11-18 Higher-Risk Myelodysplastic Syndrome
• Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended recruitment
  2023-504828-25-00 9 2020-11-16 Chronic Lymphocytic Leukemia

Showing 1,105–1,128 of 1,630 trials